ArticleJournal of translational medicine2026
Lipidomic signatures associated with cognitive impairment in type 1 diabetes mellitus: a pilot study integrating clinical serum and mouse hippocampus.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive impairment in Type 1 diabetes mellitus (T1DM) was linked to abnormal lipid metabolism, and its related metabolic alterations remain unclear. Lipidomics may provide novelty insights into the pathophysiology of cognitive impairment in T1DM.
methodsThis study aimed to explore lipidomic alterations and identify potential lipidomic signatures associated with cognitive impairment in T1DM patients and mice. In this clinical study, cognitive assessments and serum samples were obtained from T1DM patients without mild cognitive impairment (T1DM-noMCI, n = 36), T1DM patients with mild cognitive impairment (T1DM-MCI, n = 33) and healthy controls (NC, n = 32). Serum lipidomic profiles were analyzed to identify metabolites and metabolic pathways in T1DM patients. Correlation between cognitive scores and levels of differential metabolites were assessed, and the diagnostic performance of biomarkers was evaluated using receiver operator characteristic (ROC) curve. In the animal experiments, Morris water maze (MWM) tests were performed on normal control mice (NC, n = 12) and T1DM mice (n = 24). Hippocampal tissues were harvested for lipidomic analysis to detect lipid metabolic changes in T1DM mice.
resultsThe clinical serum lipidomic patterns in T1DM-noMCI and T1DM-MCI groups were significantly different from those of HCs, and metabolite alterations between T1DM-noMCI and T1DM-MCI groups were also dramatical. Pathway enrichment analysis found that T1DM-noMCI and T1DM-MCI groups had a significant impact on glycerophospholipid metabolism. Cognitive scores were negatively related to serum levels of specific metabolites. We successfully selected 13 lipidomic biomarkers to differentiate T1DM-MCI patients, with good diagnostic efficiency. The hippocampus lipidomic patterns in T1DM mice with cognitive decline were also significantly different from those of NCs, while metabolite alterations in T1DM mice with different levels of cognitive decline were dramatically similar. Notably, the lipid metabolic pathways enriched in the hippocampus of T1DM mice showed remarkable concordance with most of those identified in the clinical serum analysis.
conclusionsIn this exploratory study, specific signatures in lipid metabolism, particularly glycerophospholipid metabolism, were associated with cognitive impairment in T1DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.